EGFR and non-small cell lung carcinoma: From a practical standpoint, an important consequence of the results presented in this study is that patients with de novo and secondary TKI-treated metastatic EGFR+ NSCLC can be safely considered together in various analyses, in contrast to concerns regarding non-TKI-treated NSCLC based on earlier investigations (24–26).